Omalizumab: what benefits should we expect?
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Giménez Arnau, Anna Mariaca
- dc.contributor.author Velasco, Manelca
- dc.contributor.author Armario Hita, Jose Carlosca
- dc.contributor.author Labrador-Horrillo, Moisésca
- dc.contributor.author Silvestre Salvador, Juan Franciscoca
- dc.date.accessioned 2016-11-17T11:37:40Z
- dc.date.available 2016-11-17T11:37:40Z
- dc.date.issued 2016
- dc.description.abstract Chronic spontaneous urticaria (CSU) is a skin disease characterised by wheal appearance, swelling, itching, and painful skin. Omalizumab has been used for CSU treatment demonstrating good efficacy. To investigate the efficacy and safety of omalizumab treatment in CSU patients in real-life practice. A retrospective analysis was performed on 38 patients suffering from CSU who received 300 mg of omalizumab every four weeks. After omalizumab treatment, 68.4% of patients showed a complete response (UAS7 = 0). All the patients were able to stop treatment with corticosteroids, cyclosporine, and anti-leukotrienes, and only 39.5% of patients remained on anti-histamines. Omalizumab treatment led to a 96% and 65% decrease in emergency room and primary health care visits, respectively, as well as a reduction in the direct costs associated with the disease. No omalizumab-related adverse events were reported. Omalizumab exhibits good efficacy in alleviating the symptoms of CSU, leads to a decrease in concomitant medication use, restores patients' quality of life, and has economic benefits by reducing disease-related health care costs.ca
- dc.format.mimetype application/pdfca
- dc.identifier.citation Giménez-Arnau A, Velasco M, Armario Hita JC, Labrador-Horrillo M, Silvestre Salvador JF. Omalizumab: what benefits should we expect?. Eur J Dermatol. 2016 Aug 1;26(4):340-4. doi: 10.1684/ejd.2016.2809ca
- dc.identifier.doi http://dx.doi.org/10.1684/ejd.2016.2809
- dc.identifier.issn 1167-1122
- dc.identifier.uri http://hdl.handle.net/10230/27531
- dc.language.iso engca
- dc.publisher John Libbey Eurotextca
- dc.relation.ispartof European Journal of Dermatology. 2016 Aug 1;26(4):340-4
- dc.rights © John Libbey Eurotext http://dx.doi.org/10.1684/ejd.2016.2809ca
- dc.rights.accessRights info:eu-repo/semantics/openAccessca
- dc.subject.other Urticàriaca
- dc.title Omalizumab: what benefits should we expect?ca
- dc.type info:eu-repo/semantics/articleca
- dc.type.version info:eu-repo/semantics/acceptedVersionca